# Meta-Reflection

## Executive Summary
Forecasting Zepbound Q4 2025 global revenue. Final central estimate ~$4,100-4,200M with wide uncertainty (10th: $3,300M, 90th: $5,500M). The question closes today (Jan 25, 2026) and resolves Feb 4, 2026. Earnings expected early February 2026.

## Research Audit
- **Most useful**: Statista data giving exact quarterly revenue history, Lilly Q3 2025 earnings report with raised guidance, Barchart Jan 2026 preview
- **Limited value**: Early 2025 analyst estimates (CNBC, FactSet) were outdated after Q2-Q3 2025 blew past expectations
- **Could not access**: Barchart article full content (WebFetch failed), specific Q4 2025 Zepbound consensus estimate from FactSet/Bloomberg

## Reasoning Quality Check

*Strongest evidence FOR central estimate (~$4,100M):*
1. Multiple estimation approaches (sequential growth, YoY, company share, full-year implied) converge on $3,800-4,500M
2. Q3→Q4 seasonal strength historically present but product now more mature
3. Lilly full-year guidance of $63-63.5B constrains the range

*Strongest argument AGAINST:*
- I couldn't find a specific analyst consensus for Q4 2025 Zepbound
- The sequential growth slowdown to 6% in Q3 could signal demand saturation
- International revenue still negligible, limiting upside from expansion
- A smart disagreer might argue Q4 could be higher (~$4,500-5,000M) given historical Q4 seasonal strength

*Calibration check:*
- Question type: Measurement (what will the reported value be?)
- Uncertainty is moderate - the product has strong trajectory but exact Q4 number depends on demand dynamics
- Distribution should be right-skewed (can go significantly higher but floor is around $3,200M)

## Subagent Decision
- Did not use subagents. The question required straightforward financial data gathering and trend analysis, which was efficiently handled in the main thread.

## Tool Effectiveness
- search_exa: Very useful for finding historical revenue data and earnings reports
- web_search: Useful but returned mostly the same results as exa
- WebFetch: Failed on barchart.com (redirect to web.archive.org)
- execute_code: Useful for systematic calculation of estimates
- No actual tool failures (HTTP errors), just inability to access Barchart content

## Process Feedback
- The prompt guidance on measurement questions (current value + drift + volatility) was appropriate
- Would have benefited from access to Bloomberg/FactSet consensus data
- The seasonal pattern analysis was the most informative analytical approach

## Calibration Tracking
- 80% CI: [$3,500M, $5,100M]
- I'm about 70% confident the actual figure falls in $3,600-4,600M range
- Update triggers: If the earnings are released before resolution, the actual number would obviously resolve all uncertainty
---

## Programmatic Metrics

*Auto-generated - do not edit manually*

- **Post ID**: 41747
- **Question ID**: 41487
- **Session Duration**: 410.9s (6.8 min)
- **Cost**: $3.8443
- **Tokens**: 18,341 total (53 in, 18,288 out)
  - Cache: 1,007,324 read, 51,251 created
- **Log File**: `logs/41747_20260206_231053/20260206_231053.log`

### Tool Calls

- **Total**: 26 calls
- **Errors**: 1 (3.8%)

| Tool | Calls | Errors | Avg Time |
|------|-------|--------|----------|
| execute_code | 2 | 0 | 57ms |
| get_metaculus_questions | 1 | 1 ⚠️ | 4661ms |
| notes | 2 | 0 | 2ms |
| search_exa | 12 | 0 | 4223ms |
| web_search | 9 | 0 | 3378ms |

### Sources Consulted

- Eli Lilly Q4 2025 earnings Zepbound revenue
- Zepbound Q4 2025 global revenue sales results
- Eli Lilly Q4 2025 earnings results January 2026 Zepbound revenue
- Eli Lilly earnings report date Q4 2025 fourth quarter
- Zepbound Q4 2025 analyst estimate forecast Wall Street consensus
- https://www.barchart.com/story/news/37015541/what-to-expect-from-eli-lillys-q...
- Eli Lilly Q4 2025 earnings report Zepbound revenue analyst estimate Wall Stre...
- Lilly 2025 annual revenue guidance update Zepbound full year sales
- Eli Lilly Q3 2025 earnings results Zepbound third quarter revenue
- Eli Lilly 2025 updated revenue guidance Zepbound Q4 expectations January 2026
- Zepbound 2025 full year revenue forecast analyst estimate billion updated
- Eli Lilly Zepbound Q4 2025 revenue Wall Street estimate preview fourth quarter
- https://www.barchart.com/story/news/37015541/what-to-expect-from-eli-lillys-q...
- Eli Lilly Q4 2025 earnings preview analyst expectations Zepbound Mounjaro rev...